← Companies|Daiichi Sankyo EU
Da

Daiichi Sankyo EU

Munich DEFounded 20052,000 employees
Private CappharmaPrivateOncology
Platform: DXd EU Ops
Market Cap
N/A
All Drugs
4
Clinical Trials
8
Failed / Terminated
2
FDA Approved
0
Drug Pipeline (4 programs)
Drug NameCodePhaseTrialsModalityTargetMOAIndications
DAI-6285DAI-6285Phase 1/22ERTBETFXIaiPompe
DoxafotisoranDAI-4568Phase 33ADCLAG-3KRASG12CiAS
DAI-7966DAI-7966Preclinical2Cell TherapyCDK4/6IL-23iMG
PexavorutinibDAI-8075Preclinical1MultispecificGIP-RTROP-2 ADCMCL
Financial Documents
This is a private company — SEC filings are not available.
Catalyst Events (10)
2025-06-15
DAI-7966 Interim
MG
Past
2025-09-09
Doxafotisoran Ph3 Readout
AS
Past
2026-10-20
DAI-7966 BTD
MG
BTD
2026-11-02
Pexavorutinib Interim
MCL
Interim
2026-11-04
DAI-6285 Ph2 Data
Pompe
Ph2 Data
2026-11-28
Doxafotisoran Ph1 Dose Esc
AS
Ph1 Dose Esc
2027-02-16
Doxafotisoran Ph3 Readout
AS
Ph3 Readout
2027-03-24
DAI-6285 Ph2 Data
Pompe
Ph2 Data
2028-09-10
DAI-7966 Interim
MG
Interim
2030-10-05
Doxafotisoran Ph3 Readout
AS
Ph3 Readout